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Stem Cells in Tissue Repair and
Regeneration
Vincent Falanga1,2,3,4
The field of tissue repair and wound healing has blossomed in the past 30 years.
We have gone from recombinant growth factors, to living tissue engineering
constructs, to stem cells. The task now is to pursue true regeneration, thus
achieving complete restoration of structure and function.
Journal of Investigative Dermatology (2012) 132, 1538–1541. doi:10.1038/jid.2012.77
For most of this discussion, we will
actually mean tissue repair, with its
attendant compromise of achieving rapid
wound closure at the expense of regener-
ation. Technically, the term ‘‘wound
healing’’ implies complete restoration of
tissue (i.e., regeneration) as the outcome.
However, we believe that over time
wound healing has also come to signify
the overall processes taking place after
injury, and more so from a biological
standpoint. We should remain hopeful
that true regeneration is possible in adult
human tissues. Thus far, the evidence has
not been encouraging, except for fetal
wound healing. Even the liver, which
many erroneously cite as an example of
potential regeneration in adults, simply
gets larger after lobe resection or injury;
no true regeneration takes place. Figure 1
indicates the immense complexities that
underlie chronic wounds. Regeneration
of the tissue shown in this figure would
be extremely difficult, and would most
likely first require complete removal of
the non-healing and affected skin. There-
fore, as we approach the topic of stem
cells for wound healing/tissue repair,
we must keep clinical realities in mind
and what we can achieve with the
methods and agents currently available.
This is not meant to be a pessimistic
view, but rather to stimulate progress
toward the ultimate goal of achieving
true regeneration.
With a focus on wound healing and
tissue repair, and particularly with the
need represented by chronic non-heal-
ing human wounds, in the 1980s the
excitement centered on growth factors
(Falanga, 2005). However, in spite of
the potential envisioned for recombi-
nant growth factors, multiple clinical
trials involving thousands of patients
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failed for the most part to show any, or
more than modest, results. This failure
surprised most investigators and pharma-
ceutical companies, because growth
factors had substantial effects on many
cell types in vitro (including fibroblasts,
endothelial cells, and keratinocytes),
and they had been shown to accelerate
healing in experimental animal models.
The problem was that laboratory animals
do not suffer from chronic wounds,
and even several innovative models
could not reproduce the failure to heal
that characterizes many human chronic
wounds. Some investigators were not
deterred. They then hypothesized that
the growth factors could not penetrate
the wound bed in sufficient concen-
trations, were easily broken down
within the wound, or required complex
methods of delivery, including the
administration of several peptides in a
specific sequence and at certain concen-
trations. We even hypothesized that
growth factors were ‘‘trapped’’ or seques-
tered within the wound, for example, by
albumin or a2-macroglobulin, the latter
being a known scavenger molecule for
platelet-derived growth factor (Falanga,
2005). This final hypothesis, similar to
the others mentioned above, remains
viable. Nevertheless, the problem with
complex hypotheses is that, from a regu-
latory standpoint, it is difficult to move
from the bench to the bedside.
However, the field of wound healing,
being very important, has kept moving
forward. Tissue engineering and bio-
engineered skin constructs, first devel-
oped many years earlier, began to
dominate the field in the 1990s. Indeed,
the scientific and clinical rationale for
certain constructs, especially those com-
prising living cells such as fibroblasts,
keratinocytes, or both, was that a tissue-
like product could overcome the defi-
ciencies potentially uncovered using
growth factors. In engineering terms, a
living construct could act in a ‘‘smart’’
way, meaning that it would adapt to the
wound microenvironment, release just
enough peptide growth factors and in
the right sequence, and possibly provide
additional and much needed extra-
cellular matrix proteins. Basically, this
approach and hypothesis was a way to
admit our own ignorance about the
underpinning of failure to heal, and
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therefore relying on cells and constructs
to do the work. It should be noted that
the cells in allogeneic constructs are
not detectable after 4–6 weeks, further
suggesting that the constructs act in
a pharmacological mode, rather than
replacement therapy (Phillips et al.,
2002). There have been notable suc-
cesses with the use of bioengineered
skin, and indeed some are used in
major burns and some are approved by
the Food and Drug Administration (FDA)
for use in chronic wounds (Falanga and
Sabolinski, 1999; Marston et al., 2003).
Important lessons were learned from
these advanced therapies, which could
benefit the future clinical use of stem
cells in burns and chronic wounds. After
regulatory approval of these advanced
therapies, it was quickly noted that the
favorable results obtained during clinical
trials were not matched in clinical prac-
tice. This discrepancy was eventually
remedied, but the finding points to an
often-underestimated aspect of science
and clinical practice. We generally
adhere to the paradigm that we are
already doing our best clinically and
that new therapies will result from
further ‘‘bench’’ studies of mechanisms
of disease. In fact, in wound healing and
other diseases, it is the introduction of
a new therapy that, in turn, leads to
a better understanding of pathogenic
mechanisms. In the case of chronic
wounds, our knowledge of failure to
heal proved to be quite unsatisfactory.
As a result of the availability of new
advanced therapies and because we
desperately needed to have them work
well clinically, among other findings, we
discovered or realized the following:
that resident wound fibroblasts did not
respond well to the stimulatory actions
of growth factors; that frequent debride-
ment was also a way to remove these
and other phenotypically altered cells;
that the excessive wound exudate would
break down bioengineered skin, associated
with a shift in wound matrix metallopro-
teinases thereby impairing epitheliali-
zation; that wound bacterial coloni-
zation and the presence of biofilms
were critical parameters; and that even
the choice of wound dressings and how
they were removed could minimize
epidermal and dermal reinjury. We have
previously reviewed these abnormalities
and findings in chronic wounds (Falanga,
2005). Eventually, we developed the now
widely adhered to concept of wound bed
preparation (WBP), in which clinical and
mechanistic aspects of impaired healing
are corrected as much and as promptly as
possible (Falanga, 2000; Panuncialman
and Falanga, 2009).
It was not long before interest in stem
cells would offer fresh hope in the field
of wound healing. This interest now
dominates our time and is obscuring,
perhaps unwisely, some of the useful
approaches achieved with growth
factors and bioengineered constructs.
Turning to human embryonic stem cells
seemed attractive in principle, were one
to overcome the ethical issues regarding
their use (and which may also com-
promise the ‘‘quality’’ or reproducible
behavior of cells kept long term in
culture). After all, although not totipo-
tent (i.e., able to also form placental
tissues), embryonic stem cells are pluri-
potent and can give rise to all cells by
using appropriate culture conditions.
The ethical issues seemed to diminish
overnight when in 2007 two separate
publications described the development
of induced pluripotent stem cells (iPS
cells) from fibroblast cultures using a
cocktail of genes. One investigative
team used Oct3/4, Sox2, Klf4, and
c-Myc by retroviral delivery (Takahashi
et al., 2007), whereas the other team
group used Oct4, Sox2, Nanog, and
Lin28 by lentiviral vectors (Yu et al.,
2007). The likelihood of producing a
single iPS cell from fibroblast cultures
was relatively low (requiring 5–10
thousand cells), but a major coup had
taken place. Suddenly, human embryo-
nic stem cells and their pluripotential
capacity lost some of their attractive-
ness, because we were now able to
develop pluripotent cells from adult skin
fibroblasts. Over time, other methods
(i.e., naked DNA, proteins, etc.) of deli-
vering these and other critical repro-
gramming genes have been reported.
Questions linger about whether iPS cells
are truly embryonic-like, but nobody can
deny the importance of taking a differen-
tiated cell back to its possible origin.
For wound healing and tissue repair,
however, pluripotent stem cells remain
a problem. Pluripotentiality may not be
required to treat wounds safely, and the
teratoma concern and regulatory and
safety hurdles remain. The importance
of the immunological rejection of these
cells, recently identified as an un-
expected finding, remains to be deter-
mined. However, alternative strategies
are enjoying greater attention. Among
these are bone marrow mobilization
Some reasons for impaired healing






















Figure 1. Difficulties underlying chronic wounds. (a) Panel a on the left shows a non-healing chronic
wound attributable to a combination of venous and lymphatic disease. Both arrows point to the
nonmigrating epidermis. The solid arrow shows the steep edges at the periphery of the wound, whereas
the dashed arrow is directed at an island of fully epithelialized tissue within the wound bed, but with
continued failure of its epidermis to migrate. (b) Panel b on the right shows a diagrammatic representation
of the phases of wound healing which, in the case of chronic wounds, are not linear or predictable in their
sequence. In addition, different areas of the wound are likely to be in a different phase of wound healing.




and peripheral blood harvesting of stem
cells with apheresis after the systemic
administration of granulocyte colony-
stimulating factor, the use of stem/pro-
genitor cells from umbilical cord blood,
and culturing of multipotent (giving rise to
one tissue type) stem cells from bone
marrow, epidermis, hair, and (as reported
by the current publication by Danner
et al. this issue, 2012) sweat glands.
From a scientific and practical stand-
point (which ultimately has ramifica-
tions for safety and regulatory oversight),
an advantage of multipotent stem cells is
that we can more reliably depend on
certain surface markers and appearance
or behavior in culture to confirm that we
are growing the same type of cells. For
example, when our group first decided
to use autologous cultured cells from
bone marrow in wounds, we focused
on mesenchymal stem cells. Although
mesenchymal cell surface markers are
not specific, the combination of such mar-
kers (i.e., lineage negative and CD34 ,
positivity for CD29, CD44, CD105,
CD166), adherence to tissue culture
plastic and cell culture appearance, and
functional assays showing differentiation
to bone, cartilage, or adipose tissue,
provide a reproducible system (Falanga
et al., 2007). We could have chosen a
hematopoietic stem/progenitor cell type,
which might have been more effective,
but then we would not have known
necessarily the attributes of that cell and
we could not have ensured consistent and
reproducible cultures in our good manu-
facturing practice facilities. The mesen-
chymal stem cells we have used in
human wounds appear to differentiate
along fibroblastic pathways and, in an
animal model, do not seem to persist for
more than 30 days, in spite of them being
autologous. Nevertheless, they appear to
be promising for use in difficult wounds
and, as suggested by published reports,
may decrease scarring—a major advan-
tage in treating burns. We are intrigued
by the report by Danner et al. 2012 that
stem cells isolated from sweat glands
exhibit features highly suggestive of
endothelial cells. This raises the issue of
whether stem cell transdifferentiation or
plasticity, a process regarded by some
as controversial, is playing a role. Some
have suggested that plasticity is the result
of co-purification with dormant pluri-
potent very small embryonic-like (VSEL)
stem cells in various adult organs and
tissues (Kucia et al., 2006). VSEL stem
cells might be of interest in wound healing,
provided that an adequate yield from
apheresis could be achieved and that
the potential for tumor formation, which
is associated with embryonic stem cells,
is not as great.
The use of multipotent, rather than
pluripotent, stem cells in wound healing
appears to be beneficial and more prac-
tical at this point, given the regulatory
and safety concerns. Regulatory require-
ments continue to increase, even as
(or because) we are placing more
emphasis on translational research.
Therefore, investigators interested in
applied approaches for stem cells must
take into account whether the stem cells
they choose to study will be deemed to
be a relatively low risk in tissue repair.
Moreover, lessons from tissue engi-
neering constructs and from WBP have
taught us that true replacement of cells
may not be necessary for most wounds.
There could be a ‘‘didactic paradigm’’
whereby certain subpopulations of mul-
tipotent stem cells may ‘‘teach’’ the
wound microenvironment how to rectify
the cellular and molecular phenotypic
flaws that lead to impaired healing. It is
also plausible that recruitment of circu-
lating stem cells or neighboring tissue-
differentiated cells may take place with
the topical administration of multipotent
stem cells. The number of delivered
stem cells seems critical. In our
mesenchymal stem cell studies in
humans, we found that at least one
million autologous cultured stem cells
per cm2 of wound surface were required
to achieve a beneficial outcome.
Progress continues in our ability to
isolate stem cells, to characterize them,
and to think of ways to deliver and use
them in translational research. For now,
multipotent stem cells are more useful
for the acceleration of healing, particu-
larly owing to their generally favorable
risks/benefits ratio. Nevertheless, we do
not reject the notion that pluripotent
stem cells may ultimately find an extra-
ordinary role in wound healing. When
properly handled and controlled, such
cells could be directed toward diverse
differentiation pathways that might
bring the field of tissue repair closer to
regeneration, or true wound healing.
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Targeting the Palm: A Leap Forward
Toward Treatment of Keratin
Disorders
Wera Roth1, Mechthild Hatzfeld2 and Thomas M. Magin1
Any rational therapy benefits from an understanding of basic biology and the
simplicity of its strategy. Among keratinopathies, epidermolytic palmoplantar
keratoderma stands out by virtue of hotspot mutations in the KRT9 gene,
exclusively expressed in the palmoplantar epidermis. In this issue, Leslie Pedrioli
et al. report on the successful application of KRT9-specific siRNAs in cultured cells
and in a mouse model. The study beautifully illustrates the potency of a thorough
experimental approach and the challenges that remain, especially in its delivery.
Journal of Investigative Dermatology (2012) 132, 1541–1542. doi:10.1038/jid.2012.99
Efficacy, specificity, and potency of a drug
represent the lynchpins of a successful
therapy. In the case of genetic disorders,
onset of disease and the cell type of origin
mount additional hurdles to be overcome.
Keratinopathies are caused mostly by
dominant mutations in at least 23 of the
54 human keratin genes expressed as
the ‘‘keratin pairs’’ that typify epithelial
differentiation (Szeverenyi et al., 2008;
http://www.interfil.org). Therefore, sites
of expression reveal the major site(s)
of disease, despite the notion that
most keratinocytes express 4–10 different
keratin proteins. Further, there appears to
be reasonable genotype–phenotype corre-
lation, indicating that mutations severely
compromising the cytoskeleton’s integrity
cause more severe disease phenotypes
than those that do not. Although patho-
mechanisms of the keratinopathies are
more complex than originally thought
See related article on pg 1627
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(Coulombe and Lee, 2012), one can
reasonably argue that reducing the
expression of the mutant allele in domi-
nant keratin disorders should restore a
more functional cytoskeleton from the
intact allele, leading to greater tissue
integrity. Proof of principle stemmed
from mouse models in which the ratio of
mutant and normal keratin alleles has
been modified genetically (Cao et al.,
2001; Hesse et al., 2007).
Among keratinopathies, epidermo-
lytic palmoplantar keratoderma (EPPK)
is unique for several reasons: the expres-
sion of the culprit, KRT9, is restricted
to the upper strata of the palmo-
plantar epidermis, forming a cytoskele-
ton together with at least six additional
keratins. The majority of EPPK patients
suffer from a missense mutation in one
of the three hotspot codons, giving rise
to a focal epidermolytic keratoderma
(http://www.interfil.org). This setting
invited Leslie Pedrioli et al. (this issue,
2012) to develop an siRNA-based ther-
apy approach, testing both generic and
mutation-specific siRNAs directed against
KRT9. The team first scanned all possible
19-mer siRNAs for the repression of KRT9,
using transiently expressed luciferase
reporters to monitor specificity and
efficacy of siRNAs. Next, siRNAs that
efficiently inhibited the two prominent
KRT9 missense mutations M157V and
R163Q were identified using a similar
strategy. The best siRNAs were able to
repress a mutant KRT9 allele in the 50 pM
range, without apparently affecting the
expression of other keratins. Ultimately,
siRNAs must be delivered in situ. Unfortu-
nately, no mouse model for KRT9 is
currently available. As a first step, Leslie
Pedrioli et al. coinjected the most potent
siRNA, siR163Q-13, together with a
mutant KRT9-luciferase reporter carrying
the same mutation, into mouse foot-
pad epidermis. This delivery route had
been previously approved in a phase Ib
clinical trial for pachyonychia congenita
(Leachman et al., 2010). To test for
specificity, a wild-type KRT9-luciferase
reporter was applied together with the
above siRNA in another footpad. Despite
the limitations imposed by the nature of
the delivery, i.e., injection, the data sug-
gest that the siRNA was more specific in
repressing the mutant compared with the
normal allele.
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